[New aspects concerning drug therapy of arrhythmia].
D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000404:Ajmaline / Q000494:pharmacology; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001341:Autonomic Nervous System / Q000187:drug effects; D001949:Bretylium Compounds / Q000494:pharmacology; D006801:Humans; D008012:Lidocaine / Q000494:pharmacology; D008564:Membrane Potentials / Q000187:drug effects; D010276:Parasympatholytics / Q000494:pharmacology; D010277:Parasympathomimetics / Q000494:pharmacology; D010672:Phenytoin / Q000494:pharmacology; D011342:Procainamide / Q000494:pharmacology; D011802:Quinidine / Q000494:pharmacology; D014700:Verapamil / Q000494:pharmacology
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D001949:Bretylium Compounds; D010276:Parasympatholytics; D010277:Parasympathomimetics; D000404:Ajmaline; D010672:Phenytoin; D008012:Lidocaine; D014700:Verapamil; D011802:Quinidine; D011342:Procainamide
Neue Aspekte der medikamentösen Behandlung von Arrhythmien